Exhibit 10.34.1
2ND AMENDMENT
CONTRACT MANUFACTURING AGREEMENT
THIS AMENDMENT NUMBER 2 dated as of October 9, 2002 (the "2nd Amendment") is
made by and between The Dow Chemical Company, a Delaware corporation ("Dow") and
GelTex Pharmaceuticals, Inc., a Massachusetts corporation ("GelTex"). The
parties wish to amend the Contract Manufacturing Agreement they entered into
effective September 4, 2001 ("Agreement") as hereafter set forth. Capitalized
terms not defined herein shall have the respective meanings ascribed to them in
the Agreement.
RECITALS
WHEREAS, Dow and GelTex have previously entered into the Agreement and
subsequent Amendment One to this agreement, whereby Dow, in connection with its
obligation to manufacture and supply Product to GelTex, presently maintains an
annual Product manufacturing capacity level at the Dow Facility of [**] and
Genzyme has committed to purchase a minimum of [**];
WHEREAS, GelTex desires to increase its purchase commitment to a minimum of [**]
and Dow is willing to supply this additional quantity.
NOW THEREFORE, in consideration of the premises and of the covenants herein
contained, Dow and GelTex hereby agree as follows:
1. GelTex commits to purchase a minimum of [**] and Dow agrees to supply this
volume.
2. The purchase price will be now calculated as follows:
[**]
3. GelTex may request additional volumes in this period should they so desire.
Dow shall at all times during 2002 and 2003 retain sufficient capacity to
supply up to [**] should such amounts be requested. In the event that
GelTex requests quantities in excess of [**], Dow shall make reasonable
commercial efforts to supply these additional volumes, subject to the plant
being able to supply these volumes without undue cost being incurred by
Dow.
4. The parties acknowledge that it is GelTex's current expectation to purchase
[**]. However, both parties agree that this is only a current expectation,
but not an obligation.
5. Both parties agree to revoke the average pricing letter dated 2nd July
2002, and Dow will reconcile the sales revenue differences on product
shipped to date between the terms of the average pricing letter and the
price as described in 2 above. Monies owing by GelTex
[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.
will be paid in full within fifteen (15) days following presentation of a
miscellaneous invoice, and any support that may reasonably be requested by
GelTex.
6. The parties will continue to discuss the possibility of entering into a
purchase agreement for the supply of [**].
[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment Number 2
to be executed by their duly authorized representatives effective as of the date
set forth above.
THE DOW CHEMICAL COMPANY
By: /s/ GG Bompa
Name: GG Bompa
Title: Commercial Director
GELTEX PHARMACEUTICALS, INC.
By: /s/ Xxxxxx Xxxxxxx
Name: Xxxxxx Xxxxxxx
Title: Senior VP and General Manager
[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.
